ReviewClinical and translational radiation oncology2027
Tumour hypoxia in clinical oncology: imaging, therapeutic strategies, and translational challenges.
Review in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia, a defining feature of many solid tumours, arises from rapid cellular proliferation, abnormal tumour stroma, and aberrant vasculature. Reduced oxygen availability contributes to several cancer hallmarks, including sustained proliferative signalling, angiogenesis, metabolic reprogramming, immune evasion, invasion, and metastasis. Consistent with these biological effects, tumour hypoxia is associated with poorer prognosis across multiple cancer types, irrespective of treatment modality. Consequently, the characterisation and therapeutic leverage of hypoxic tumour status have been key areas of clinical investigation over the past three decades. However, despite extensive research, no method for routine clinical stratification of tumours by hypoxic status has been widely adopted, and hypoxia-targeted or hypoxia-alleviating treatments remain limited in clinical use. This review summarises the clinical progress and ongoing challenges in hypoxia imaging and therapeutic intervention. It focuses on strategies designed to enhance oxygen delivery, exploit hypoxic tumour environments through hypoxia-activated prodrugs, or modify tumour oxygen consumption. By these approaches under clinical evaluation, this review aims to identify key barriers to the integration of hypoxia-focused intervention and highlight the volume and diversity of hypoxia targeted treatments that are pending clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.